Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

37.44
+0.58001.57%
Post-market: 37.510.1000+0.27%16:31 EDT
Volume:2.43M
Turnover:92.88M
Market Cap:6.96B
PE:-10.47
High:39.14
Open:37.89
Low:37.40
Close:36.86
Loading ...

Company Profile

Company Name:
Revolution Medicines, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
534
Office Location:
700 Saginaw Drive,Redwood City,California,United States
Zip Code:
94063
Fax:
- -
Introduction:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Directors

Name
Position
Mark A. Goldsmith
President, Chief Executive Officer and Director
Alexis Borisy
Director
Barbara Weber
Director
Elizabeth McKee Anderson
Director
Larry Lasky
Director
Neil Exter
Director
Thilo Schroeder
Director
Vincent A. Miller
Director

Shareholders

Name
Position
Mark A. Goldsmith
President, Chief Executive Officer and Director
Margaret Horn
Chief Operating Officer and General Counsel
Jack Anders
Vice President, Finance and Principal Accounting Officer
Steve Kelsey
President, Research and Development